Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 5/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.31 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6793455 | 0.87 | KDM1A (0.36) | RORCPDPK1CDK2OPRD1AVPR2 | |
| SCHEMBL6794891 | 0.87 | RORC (0.34) | RORCPDPK1CDK2MAPTALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL6794900 | 0.87 | RORC (0.34) | RORCPDPK1CDK2ALDH1A1OPRD1 | |
| Trifluoroacetic Acid SCHEMBL6787805 | 0.85 | CDK2 (0.36) | RORCPDPK1CDK2HCAR2S1PR1 | |
| Trifluoroacetic Acid SCHEMBL6791711 | 0.84 | BRAF (0.38) | PDPK1CDK2OPRD1KDM1A | |
| Trifluoroacetic Acid SCHEMBL6792875 | 0.84 | GABRA1 (0.34) | RORCPDPK1CDK2S1PR1OPRD1 | |
| Trifluoroacetic Acid SCHEMBL6792278 | 0.84 | RORC (0.36) | RORCPDPK1CDK2S1PR1OPRD1 | |
| Trifluoroacetic Acid SCHEMBL6791782 | 0.84 | PDPK1 (0.33) | RORCPDPK1CDK2OPRD1 | |
| Trifluoroacetic Acid SCHEMBL1655968 | 0.83 | MPL (0.39) | PDPK1CDK2S1PR1KDM1A | |
| Trifluoroacetic Acid SCHEMBL6794064 | 0.83 | NR1H4 (0.33) | PDPK1CDK2OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | RORC 1054/4885PDPK1 87/4885CDK2 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.